Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of generic dutasteride + tamsulosin fixed-dose combination vs Duodart in healthy Thai males (fasting, single-dose, crossover)
TCTR20260702001Phase 1Not yet recruiting
- Sponsor
- International Bio Service
- Start
- Jul 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of alpha blocker + 5-alpha reductase inhibitor, dutasteride and tamsulosin in benign prostatic hyperplasia (BPH) (2 arms), sponsored by International Bio Service. Planned start Jul 2026; status: not yet recruiting.
02
Drugs
alpha blocker + 5-alpha reductase inhibitordutasteridetamsulosin
03
Conditions
benign prostatic hyperplasia (BPH)
Beyond the preview
Go deeper on TCTR20260702001.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on TCTR20260702001.